Krebs Biochemicals and Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2025
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krebs Biochemicals has called its 33rd AGM on Friday, September 26, 2025 at 11:30 AM at its registered office in Andhra Pradesh. Key resolutions include appointing Mr. Manish Kumar Jain as Managing Director and CEO for 5 years (w.e.f. August 7, 2025) at Rs. 2.5 lakh per month, re-appointing statutory auditors M/s. Bhavani & Co. for an extended 5-year term till 2029, and approving related party transactions with promoter Ipca Laboratories Limited up to Rs. 120 crore. The company also seeks to appoint M/s. DSMR & Associates as secretarial auditors for 5 years from FY26. E-voting via KFintech runs from September 23 (9 AM) to September 25 (5 PM), with cut-off date September 19. The FY25 results show a loss after tax of Rs. 26.94 crore on total income of Rs. 44.02 crore, with negative net worth of Rs. 146.24 crore and book value at minus Rs. 67.83 per share — the fifth straight year of losses.
Shareholders should weigh the Rs. 120 crore related party transaction limit with promoter Ipca Laboratories carefully given the company's distressed financial position (negative book value, five consecutive years of losses, and eroding reserves). The new MD & CEO appointment signals a possible management reset, but the company's weak fundamentals and lack of profitability remain key concerns for investors.